Resin cleavage: difference between revisions
Diff·revision 3 → 4·21:00, 5 Sep 2024
Difference between revision 3 and revision 4 of Resin cleavage. 3 lines changed; the page grew by 407 bytes.
| Revision 3 — 02:34, 23 Aug 2024 FreightFenna (talk) expand §Isolation 1,678 bytes ±0 | Revision 4 — 21:00, 5 Sep 2024 StopperingSteff (talk) add the collapse-temperature point, sourced 2,085 bytes +407 | ||
|---|---|---|---|
| 15 | Time and temperature are the other variables. Arginine's sulfonyl protecting groups are the slowest to remove, so a peptide rich in arginine requires longer treatment — during which more sensitive residues are exposed to acid for longer. | 15 | Time and temperature are the other variables. Arginine's sulfonyl protecting groups are the slowest to remove, so a peptide rich in arginine requires longer treatment — during which more sensitive residues are exposed to acid for longer. |
| 16 | 16 | ||
| + | 17 | The trade-off is direct: insufficient time leaves protected species in the crude, excessive time generates degradation. This is one of the process choices that a [[Certificate of analysis|certificate]] does not report but whose consequences it may show.{{r|usp1503}} | |
| + | 18 | ||
| 17 | == References == | 19 | == References == |
| 18 | {{reflist}} | 20 | {{reflist}} |
| 19 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> | 21 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> |
| + | 22 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 20 | 23 | ||
| 21 | {{DEFAULTSORT:Resin cleavage}} | 24 | {{DEFAULTSORT:Resin cleavage}} |